Q-omics provides the consensus-scored COMMD1 profile across patient tissues and cancer cell-line models. COMMD1 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, COMMD1 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, COMMD1 protein abundance shows 19,340 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, KIRC, and GBM as cancer lineages where COMMD1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for COMMD1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes COMMD1 survival associations across molecular data types. COMMD1 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (3) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible COMMD1 RNA expression–survival associations across cancer types. High COMMD1 expression shows unfavorable associations in ACC, UCS, STAD, KICH and LGG, but favorable associations in KIRC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for COMMD1 RNA expression.
This table summarizes COMMD1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for COMMD1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. COMMD1 shows lower tumor expression in KICH and THCA and higher tumor expression in KIRC, LIHC, CHOL and LUSC. The KIRC box plot shows higher COMMD1 RNA expression in tumor versus normal tissue (log2 FC = +0.464, t-test p < 0.001).
This table shows molecular features associated with COMMD1 in patient tissues and cancer cell lines. In patient samples, COMMD1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, COMMD1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in OVARY and UPPER_AERODIGESTIVE_TRACT.
